Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Garau

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|July 13, 2026
Optimisation or Restriction? Unpacking the Logic Behind NICE DecisionsNadine Henderson, Brittany Darrow, Phill O'Neill, et al.
Journal of Comparative Effectiveness Research|March 6, 2015
Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020Adrian Towse, Martina Garau, Penny Mohr, et al.
Journal of Comparative Effectiveness Research|March 3, 2015
The future of comparative effectiveness and relative efficacy of drugs: an international perspectiveDonna A Messner, Adrian Towse, Penny Mohr, et al.
International Journal of Technology Assessment in Health Care|February 13, 2016
IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDYMartina Garau, Koonal Kirit Shah, Priya Sharma, et al.
BMJ (Clinical Research Ed.)|December 17, 2004
Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective studyA H Miners, Martina Garau, Dogan Fidan, et al.
Personalized Medicine|May 23, 2018
Can and should value-based pricing be applied to molecular diagnostics?Martina Garau, Adrian Towse, Louis Garrison, et al.
Pharmacoeconomics - Open|April 7, 2018
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)Martina Garau, Grace Hampson, Nancy Devlin, et al.
Orphanet Journal of Rare Diseases|May 5, 2019
Comparing access to orphan medicinal products in EuropeBernarda Zamora, Francois Maignen, Phill O'Neill, et al.
International Journal of Technology Assessment in Health Care|July 15, 2015
PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCHRachael Moloney, Penny Mohr, Emma Hawe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
A pilot study of multicriteria decision analysis for valuing orphan medicinesJon Sussex, Pierrick Rollet, Martina Garau, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|July 13, 2026
Optimisation or Restriction? Unpacking the Logic Behind NICE DecisionsNadine Henderson, Brittany Darrow, Phill O'Neill, et al.
Journal of Comparative Effectiveness Research|March 6, 2015
Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020Adrian Towse, Martina Garau, Penny Mohr, et al.
Journal of Comparative Effectiveness Research|March 3, 2015
The future of comparative effectiveness and relative efficacy of drugs: an international perspectiveDonna A Messner, Adrian Towse, Penny Mohr, et al.
International Journal of Technology Assessment in Health Care|February 13, 2016
IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDYMartina Garau, Koonal Kirit Shah, Priya Sharma, et al.
BMJ (Clinical Research Ed.)|December 17, 2004
Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective studyA H Miners, Martina Garau, Dogan Fidan, et al.
Personalized Medicine|May 23, 2018
Can and should value-based pricing be applied to molecular diagnostics?Martina Garau, Adrian Towse, Louis Garrison, et al.
Pharmacoeconomics - Open|April 7, 2018
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)Martina Garau, Grace Hampson, Nancy Devlin, et al.
Orphanet Journal of Rare Diseases|May 5, 2019
Comparing access to orphan medicinal products in EuropeBernarda Zamora, Francois Maignen, Phill O'Neill, et al.
International Journal of Technology Assessment in Health Care|July 15, 2015
PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCHRachael Moloney, Penny Mohr, Emma Hawe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
A pilot study of multicriteria decision analysis for valuing orphan medicinesJon Sussex, Pierrick Rollet, Martina Garau, et al.
Pageof 2